◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SLS

Sellas Life Sciences Group Inc (SLS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-29

Sellas Life Sciences Group Inc (SLS) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 13 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SLS reported $0M in revenue and ($27M) in net income.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

Interactive charts & full statements →

SLS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	—	$0M	$0M	$0M	$1M	$8M	$0M	$0M	$0M	$0M	$0M	$0M	$9M	$2M	$2M	$0M	—	—	—	—	—
Operating Income (EBIT)	($35M)	($28M)	($32M)	($38M)	($42M)	($25M)	($17M)	($20M)	($32M)	($16M)	($16M)	($34M)	($37M)	($34M)	($21M)	($21M)	($17M)	($18M)	($15M)	($11M)	($2M)
Operating Margin %	—	—	—	—	-4195.0%	-332.8%	-893789.5%	—	—	—	—	—	-392.8%	-1360.7%	-1040.2%	—	—	—	—	—	—
Net Income	($32M)	($27M)	($31M)	($37M)	($41M)	($21M)	($17M)	($19M)	($28M)	($24M)	($24M)	($64M)	($37M)	($77M)	($35M)	($11M)	($12M)	($18M)	($14M)	($11M)	($2M)
Net Margin %	—	—	—	—	-4130.1%	-272.4%	-881947.4%	—	—	—	—	—	-392.8%	-3083.1%	-1715.8%	—	—	—	—	—	—
EBITDA	($25M)	($27M)	$1M	$1M	($31M)	($18M)	$27M	$1M	($33M)	($23M)	($16M)	($37M)	($37M)	$8M	($21M)	($11M)	($12M)	($18M)	($14M)	($11M)	($2M)
Earnings Per Share (EPS)	$-0.21	$-0.25	$-0.50	$-1.34	$-2.13	$-1.34	$-2.10	$-7.54	$-105.80	$-507.49	$-70.94	$-3,195.10	$-1,022.20	$-2,834.26	$-1,866.21	$-1,053.77	$-2,177.38	$-3,783.33	$-3,486.90	$-2,893.63	$-636.24
Shares Outstanding (M)	189M	109M	61M	28M	19M	15M	8M	3M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SLS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Operating Income (EBIT)	($11M)	($9M)	($8M)	($7M)	($7M)	($6M)	($7M)	($7M)
Operating Margin %	—	—	—	—	—	—	—	—
Net Income	($10M)	($8M)	($8M)	($7M)	($7M)	($6M)	($7M)	($7M)
Net Margin %	—	—	—	—	—	—	—	—
EBITDA	($10M)	($8M)	($8M)	$0M	($7M)	($6M)	($7M)	($7M)
Earnings Per Share (EPS)	$-0.05	$-0.05	$-0.05	$-0.06	$-0.07	$-0.07	$-0.09	$-0.10
Shares Outstanding (M)	189M	172M	153M	108M	99M	88M	74M	68M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SLS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($28M)	($28M)	($35M)	($31M)	($24M)	($26M)	($10M)	($18M)	($30M)	($11M)	($45M)	($48M)	($43M)	($29M)	($21M)	($15M)	($10M)	($12M)	($9M)	($6M)	($2M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$6M	$4M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$6M	$16M	$1M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($28M)	($28M)	($35M)	($37M)	($28M)	($26M)	($10M)	($18M)	($30M)	($11M)	($45M)	($48M)	($48M)	($45M)	($22M)	($15M)	($10M)	($12M)	($10M)	($6M)	($2M)
FCF Margin %	—	—	—	—	-2830.9%	-342.4%	-548263.2%	—	—	—	—	—	-519.3%	-1799.6%	-1064.9%	—	—	—	—	—	—
Dividends Paid	—	—	—	—	—	—	—	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SLS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($8M)	($9M)	($5M)	($7M)	($7M)	($9M)	($7M)	($8M)
Free Cash Flow (FCF)	($8M)	($9M)	($5M)	($7M)	($7M)	($9M)	($7M)	($8M)
FCF Margin %	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SLS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$145M	$78M	$19M	$6M	$21M	$26M	$46M	$17M	$17M	$34M	$66M	$82M	$80M	$88M	$55M	$31M	$7M	$6M	$10M	$12M	$0M
Cash & Cash Equivalents	$138M	$72M	$14M	$3M	$17M	$21M	$35M	$7M	$5M	$2M	$18M	$30M	$24M	$48M	$33M	$11M	$7M	$6M	$10M	$2M	$0M
Total Liabilities	$8M	$7M	$10M	$14M	$16M	$6M	$18M	$11M	$12M	$31M	$37M	$69M	$43M	$82M	$27M	$21M	$5M	$6M	$1M	$1M	—
Total Debt (Short + Long-Term)	$1M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$11M	$22M	$16M	$8M	$10M	$0M	$1M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$138M	$71M	$9M	($8M)	$5M	$20M	$28M	$6M	$5M	$2M	$29M	$14M	$37M	$6M	$28M	$10M	$2M	$1M	$9M	$11M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SLS viewer.

Other Companies in BIOTECHNOLOGY

VRDN · Viridian Therapeutics Inc — $2 billion
MLYS · Mineralys Therapeutics, Inc. Common Stock — $2 billion
VERA · Vera Therapeutics Inc — $2 billion
HRMY · Harmony Biosciences Holdings — $2 billion
NKTR · Nektar Therapeutics — $2 billion
AUPH · Aurinia Pharmaceuticals Inc — $2 billion
GENB · Generate Biomedicines, Inc. Common Stock — $2 billion
OCUL · Ocular Therapeutix Inc — $2 billion

← SLRM All “S” companies SLSA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.